Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 12, 2026

4 Leveraged ETF Winners of Last Week

View original at finance.yahoo.com
4 Leveraged ETF Winners of Last Week Wall Street offered an upbeat performance last week. State Street SPDR S&P 500 ETF Trust SPY has added about 2.4% last week…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The labor market is stable rather than strong.

    60% confidence

  • Kalshi traders see a 58% probability that a U.S.-Iran deal is reached by 2027.

    60% confidence

  • Kalshi traders see a 47% probability that a U.S.-Iran agreement is reached by September 2026.

    60% confidence

  • Q1 earnings estimates have moved higher for 7 of the 16 Zacks sectors: Tech, Energy, Basic Materials, Utilities, Industrials, Retail, and Business Services.

    60% confidence

  • Micron Technology is one of the leading worldwide providers of semiconductor memory solutions.

    60% confidence

  • In mid-April 2026, odds that the U.S. and Iran reach a nuclear deal by June were more than 70%.

    60% confidence

  • Markets currently expect the Federal Reserve to leave rates unchanged through the remainder of the year as inflation remains elevated and the labor market cools only gradually.

    60% confidence

  • The United States was expecting a response on Friday from Iran on the proposal to end the war.

    60% confidence

Data points we hold from this source

United States Government · population4.3 percent_unemployment_rate
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
4 Leveraged ETF Winners of Last Week — Source | Via News | ViaNews Market